AbirateroneSolubilityInclusion complexHydroxypropyl-β-cyclodextrinAbiraterone acetate (ABA), a precursor drug inhibiting androgen biosynthesis (CYP17 inhibitor), is used for treating metastatic castration-resistant prostate cancers. However, it falls under the Biopharmaceutical Classification System Class IV due...
Abiraterone acetate (Zytiga?) Abiraterone acetate (often shortened to abiraterone) is a hormonal therapy drug used to treat advanced prostate cancer. It is also known as Zytiga?. View all Originator Abiraterone,Cougar Uses Prasteronyl Abiraterone is a dimer impurity of Abiraterone (A108490), a ...
PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol. 2015;67:795–802. Article CAS Google Scholar Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced ...
Abiraterone acetate was developed at The Institute of Cancer Research, which therefore has a commercial interest in the development of this agent. CP received lecture fees from Sanofi-Aventis and travel support from Sanofi-Aventis and Janssen-Cilag. JSdB received consulting fees from Ortho Biotech Onc...
Abiraterone acetate, Bone metastases, Castrate-resistant prostate cancer, Disseminated intravascular coagulation Introduction Disseminated intravascular coagulation (DIC) is a rare, but well-known complication of advanced prostate carcinoma. Usually, the activation of the hemostatic system is minimal since neg...
DRUG side effectsPROSTATE-specific antigenABIRATERONE acetatePROGRESSION-free survivalPurpose: The proper treatment sequence for administering abiraterone acetate plus prednisolone (AAP) and chemotherapeutic agents has not yet been elucidated for metastatic castration-resistant prostate cancer (mCRPC)...